Literature DB >> 12361398

New PET imaging agent for the serotonin transporter: [(18)F]ACF (2-[(2-amino-4-chloro-5-fluorophenyl)thio]-N,N-dimethyl-benzenmethanamine).

Shunichi Oya1, Seok Rye Choi, Heinz Coenen, Hank F Kung.   

Abstract

A new F-18-labeled phenylthiophenyl derivative specific for imaging of serotonin transporters (SERT) in the brain by positron emission tomography (PET) is described. Fluorinated phenylthiophenyl derivative, ACF, 2-[(2-amino-4-chloro-5-fluorophenyl)thio]-N,N-dimethyl-benzenmethanamine, was prepared by first coupling 2,5-dichloro-4-nitroaniline with 2-mercapto-N,N-dimethylbenzamide. The amino group of the coupled adduct was converted to a fluoro group through a Schiemann reaction. Subsequently, a one pot reduction of both nitro and amide groups by BH(3)-tetrahydrofuran yielded the nonradioactive ACF (yield 25%). In vitro binding assays using cell membrane homogenates of LLC cells expressing SERT, dopamine transporters (DAT), or norepinephrine transporters (NET) showed excellent binding affinity and selectivity for SERT (K(i) = 0.05, 3020, and 650 nM for SERT, DAT, and NET, respectively). For preparation of the [(18)F]ACF, the NH(2) group of the initially coupled adduct was converted to the trimethylammonium salt, which was replaced by [(18)F]fluoride in the presence of Kryptofix 222 and potassium carbonate. The final product, [(18)F]ACF, was obtained after a borane and stannous chloride reduction reaction. The combined two step reaction gave a radiochemical yield of 10-15% (EOB) and a radiochemical purity of >99%. Synthesis of the novel PET tracer, [(18)F]ACF, as a probe for binding to SERT in the brain was successfully achieved. The new tracer [(18)F]ACF showed excellent brain penetration and selective localization after an iv injection in rats (brain uptake at 2, 30, 60, 120, and 240 min was 3.27, 1.28, 0.69, 0.21, and 0.06% dose/organ, respectively). The hypothalamus/cerebellum ratio at 60 min post iv injection was 3.55. This specific localization in the hypothalamus was blocked by pretreatment of (+)McN5652. This novel ligand is a potential PET tracer for in vivo evaluation of SERT in the brain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12361398     DOI: 10.1021/jm020167y

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.

Authors:  Julie L Wang; Shunichi Oya; Ajit K Parhi; Brian P Lieberman; Karl Ploessl; Catherine Hou; Hank F Kung
Journal:  Nucl Med Biol       Date:  2010-05       Impact factor: 2.408

2.  PET imaging of the brain serotonin transporters (SERT) with N,N-dimethyl-2-(2-amino-4-[18F]fluorophenylthio)benzylamine (4-[18F]-ADAM) in humans: a preliminary study.

Authors:  Wen-Sheng Huang; San-Yuan Huang; Pei-Shen Ho; Kuo-Hsing Ma; Ya-Yao Huang; Chin-Bin Yeh; Ren-Syuan Liu; Cheng-Yi Cheng; Chyng-Yann Shiue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-05       Impact factor: 9.236

3.  Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors:  Jeffrey S Stehouwer; Mark M Goodman
Journal:  PET Clin       Date:  2009-01

4.  5-Chloro-2-(2'-((dimethylamino)methyl)-4'-iodophenylthio)benzenamine: a new serotonin transporter ligand.

Authors:  Shunichi Oya; Seok-Rye Choi; Mei-Ping Kung; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-02       Impact factor: 2.408

5.  Preliminary Results on the Long-Term Effects of Dextromethorphan on MDMA-Mediated Serotonergic Deficiency and Volumetric Changes in Primates Based on 4-[18F]-ADAM PET/MRI.

Authors:  Skye Hsin-Hsien Yeh; Yu-Yeh Kuo; Wen-Sheng Huang; Chuang-Hsin Chiu; Tsung-Hsun Yu; Leo Garcia Flores Ii; Chi-Jung Tsai; Cheng-Yi Cheng; Kuo-Hsing Ma
Journal:  Front Neurosci       Date:  2022-05-19       Impact factor: 5.152

6.  2-(2'-((Dimethylamino)methyl)-4'-(3-[(18)F]fluoropropoxy)-phenylthio)benzenamine for positron emission tomography imaging of serotonin transporters.

Authors:  Julie L Wang; Ajit K Parhi; Shunichi Oya; Brian Lieberman; Mei-Ping Kung; Hank F Kung
Journal:  Nucl Med Biol       Date:  2008-05       Impact factor: 2.408

7.  Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[18F]-ADAM in rats and monkeys.

Authors:  Ya-Yao Huang; Kuo-Hsing Ma; Ta-Wei Tseng; Ta-Kai Chou; Hanna Ng; Jon C Mirsalis; Ying-Kai Fu; Tieh-Chi Chu; Wen-Sheng Huang; Chyng-Yann Shiue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-10       Impact factor: 9.236

8.  2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.

Authors:  Ajit K Parhi; Julie L Wang; Shunichi Oya; Seok-Rye Choi; Mei-Ping Kung; Hank F Kung
Journal:  J Med Chem       Date:  2007-12-04       Impact factor: 7.446

9.  Effects of MDMA on blood glucose levels and brain glucose metabolism.

Authors:  M L Soto-Montenegro; J J Vaquero; C Arango; G Ricaurte; P García-Barreno; M Desco
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-12       Impact factor: 10.057

10.  Recent progress of imaging agents for Parkinson's disease.

Authors:  Xiaoai Wu; Huawei Cai; Ran Ge; Lin Li; Zhiyun Jia
Journal:  Curr Neuropharmacol       Date:  2014-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.